Biophytis S.A. (BPTSY) - Total Assets
Based on the latest financial reports, Biophytis S.A. (BPTSY) holds total assets worth $8.71 Million USD as of June 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Biophytis S.A. (BPTSY) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Biophytis S.A. - Total Assets Trend (2012–2023)
This chart illustrates how Biophytis S.A.'s total assets have evolved over time, based on quarterly financial data. Explore Biophytis S.A. long-term investment allocation to see how much of total assets are deployed in long-term investments.
Biophytis S.A. - Asset Composition Analysis
Current Asset Composition (December 2023)
Biophytis S.A.'s total assets of $8.71 Million consist of 74.0% current assets and 26.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 46.6% |
| Accounts Receivable | $2.74 Million | 22.9% |
| Inventory | $45.00K | 0.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $2.64 Million | 22.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2023)
This chart illustrates how Biophytis S.A.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Biophytis S.A..
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biophytis S.A.'s current assets represent 74.0% of total assets in 2023, a decrease from 95.4% in 2012.
- Cash Position: Cash and equivalents constituted 46.6% of total assets in 2023, down from 51.5% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 22.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 22.9% of total assets.
Biophytis S.A. Competitors by Total Assets
Key competitors of Biophytis S.A. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Biophytis S.A. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.41 | 0.81 | 0.72 |
| Quick Ratio | 0.41 | 0.80 | 0.72 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-8.35 Million | $-2.68 Million | $-5.71 Million |
Biophytis S.A. - Advanced Valuation Insights
This section examines the relationship between Biophytis S.A.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.26 |
| Latest Market Cap to Assets Ratio | 0.35 |
| Asset Growth Rate (YoY) | -45.6% |
| Total Assets | $11.96 Million |
| Market Capitalization | $4.19 Million USD |
Valuation Analysis
Below Book Valuation: The market values Biophytis S.A.'s assets below their book value (0.35x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Biophytis S.A.'s assets decreased by 45.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Biophytis S.A. (2012–2023)
The table below shows the annual total assets of Biophytis S.A. from 2012 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $11.96 Million | -45.60% |
| 2022-12-31 | $21.99 Million | -39.37% |
| 2021-12-31 | $36.26 Million | +33.27% |
| 2020-12-31 | $27.21 Million | +53.97% |
| 2019-12-31 | $17.67 Million | -19.17% |
| 2018-12-31 | $21.86 Million | -15.74% |
| 2017-12-31 | $25.95 Million | +209.15% |
| 2016-12-31 | $8.39 Million | -37.91% |
| 2015-12-31 | $13.52 Million | +3393.95% |
| 2014-12-31 | $386.86K | -38.38% |
| 2013-12-31 | $627.76K | -48.11% |
| 2012-12-31 | $1.21 Million | -- |
About Biophytis S.A.
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics targets and activates key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, … Read more